Pharma
Commented by André Will-Laudien on October 24th, 2024 | 07:30 CEST
Biotech – Are takeovers looming amidst curious prices? Evotec, Bayer, Vidac Pharma and BioNTech in the spotlight
The biotech sector is once again in the spotlight. Since the acquisition of MorphoSys at the beginning of the year, the speculation carousel is turning again. Is Evotec next, or maybe Vidac Pharma? The Hamburg-based drug specialist came under fire from short-sellers after the resignation of long-standing CEO Lanthaler, who had shorted over 4% of the capital by mid-September. However, the price stubbornly held above the EUR 5 mark, and yesterday saw a 10% rise to EUR 6.60. What is behind this? Last week, it was Vidac Pharma that surged 300% from a standing start with enormous trading volumes. The thought processes of market participants are evident: interest rates are falling, making refinancing attractive again for upcoming financial investors. We shed light on the key players.
Read
Commented by Armin Schulz on October 23rd, 2024 | 08:00 CEST
Evotec, Nyxoah, BioNTech – Stocks for the future?
The biotechnology and medtech industries are at an exciting turning point, with companies such as Evotec, Nyxoah and BioNTech positioning themselves as leading players in this dynamic field. Their innovative technologies and promising product pipelines could have the potential to fundamentally transform healthcare. Evotec excels in drug discovery expertise, Nyxoah develops groundbreaking solutions for sleep apnea, and BioNTech is a pioneer in mRNA technology. Although Evotec and BioNTech have recently faced challenges, all three companies are well-positioned to benefit from future medical developments.
Read
Commented by Fabian Lorenz on October 23rd, 2024 | 07:30 CEST
More than 100% upside potential! Bayer, Plug Power and 123fahrschule – Which stock is convincing?
Analysts see more than a 100% upside potential in the 123fahrschule stock. The exciting second-line stock wants to make driver education more modern and efficient and is getting support from politicians. Accordingly, sales and profits should rise sharply. Plug Power can also show rising sales, but like industry colleague Nel, the Americans are unable to get a grip on their losses. Will the quarterly figures turn things around? Bayer shareholders have been waiting for a turnaround for quite some time. But analysts also expect falling profits in the coming quarterly report. Is there still potential for a 40% increase in the DAX share?
Read
Commented by Stefan Feulner on October 17th, 2024 | 08:00 CEST
Bavarian Nordic, NYXOAH, Rani Therapeutics - Biotechnology on the verge of a quantum leap
The future looks promising for biotechnology. The factors pointing to this are plain to see. Besides short-term stimuli such as the decline in inflation and potential further interest rate cuts, demographic change is providing a tailwind. By 2060, the global population over the age of 65 is expected to reach 1.7 billion. In addition, increasing prosperity is contributing to lifestyle diseases such as obesity and diabetes. Furthermore, the pharmaceutical industry urgently needs new products from innovative biotech companies, as numerous patents are set to expire in the coming years.
Read
Commented by Juliane Zielonka on October 17th, 2024 | 07:15 CEST
Saturn Oil + Gas, Bayer, Siemens Energy: Three companies for balance in volatile times
In uncertain times like these, a balanced portfolio is crucial for every investor. Also, in view of the upcoming US election, diversification across different sectors is worthwhile to offset fluctuations in the portfolio. Saturn Oil & Gas relies on a combination of share buybacks and targeted acquisitions. With an adjusted EBITDA of approximately CAD 400 million, the Company is demonstrating its financial strength and potential for further growth. By applying for approval of a drug for menopausal symptoms to the European Medicines Agency (EMA), Bayer AG is targeting a global market that is expected to grow to a remarkable USD 26.97 billion by 2031. Global player Siemens Energy is focusing on the reorganization of its wind business and its participation in offshore wind energy projects. The early contract extension of CEO Christian Bruch until 2030 underlines the confidence in the current course. Today, we have three companies in focus.
Read
Commented by Armin Schulz on October 15th, 2024 | 07:15 CEST
Volkswagen and Bayer with problems – 123fahrschule, on the other hand, with great growth potential
As the German economy undergoes a profound transformation, traditional industries are facing significant challenges. Giants like Volkswagen and Bayer are experiencing difficult times with shrinking margins and structural changes. Volkswagen, Europe's leading automaker, is struggling with falling profits in its core brand despite high group earnings and is planning rigorous cost-cutting measures that could jeopardize jobs. Similarly, Bayer is being forced to make extensive job cuts and reorganize. However, in the midst of these crises, new opportunities are also emerging: companies like 123fahrschule are using innovative strategies to thrive in the education sector. Today, we take a closer look at these three companies.
Read
Commented by Stefan Feulner on October 14th, 2024 | 07:00 CEST
Bayer, Vidac Pharma, Evotec – Enormous potential
Since the US Federal Reserve cut key interest rates and signaled a continuation of its loose monetary policy, the Nasdaq Biotech Index has been on an upward trajectory and has significantly outperformed the broader market in recent days. The correction of the past few months seems to be over in this sector, and the all-time high from August 2021 is within reach. In addition to rising share prices, the number of acquisitions is also increasing significantly, a sign of the undervaluation of many listed companies.
Read
Commented by Fabian Lorenz on October 9th, 2024 | 07:15 CEST
Biotech comeback and takeover fantasy! BioNTech, Bayer, and Vidac Pharma
Money can be made in biotech shares again! However, investors need to look carefully. While Moderna is at a multi-year low, BioNTech and Vidac Pharma have gained over 50% in just a few months. Is there more to come? The chances are good, as both biotech companies have released promising news. Analysts see a tenfold increase in the case of Vidac Pharma, and the focus on the fight against cancer makes the Company a takeover candidate. The cancer specialist would also be a good fit for Bayer and BioNTech, and the share is still cheap. BioNTech is becoming an investment darling again and is focusing on AI. Bayer has yet to make the leap above EUR 30, and analysts are warning about the upcoming quarterly figures.
Read
Commented by Fabian Lorenz on October 3rd, 2024 | 14:05 CEST
100% with HelloFresh! Are Bayer and dynaCERT taking off next?
Since the low in June, the HelloFresh share has roughly doubled. Not bad for an MDAX-listed stock with a market capitalization of EUR 1.6 billion. Can it continue at this pace, or would it be better to take profits? Analysts weigh in with their assessment. dynaCERT shows great potential. With a new German CEO, the Canadian company aims to make diesel engines more efficient and low-emission in Europe. And what is Bayer doing? Will the positive news flow help it to break out of the consolidation?
Read
Commented by Juliane Zielonka on October 3rd, 2024 | 14:00 CEST
Vidac Pharma, BioNTech, Gerresheimer optimize the value chain - From research to patient
Medical innovation and rapid therapy development are gaining momentum thanks to the use of AI. In this context, companies in the pharmaceutical and biotech industry are relying on groundbreaking technologies and strategies to optimize the value chain from research to patient. Vidac Pharma is researching an innovative approach to fighting cancer by supporting the body's own immune defenses. The Company has now received a patent in the US, granting exclusivity. BioNTech is using AI-powered research to bring innovative therapies to patients more quickly. Gerresheimer is producing advanced packaging solutions for pharmaceuticals that have the potential to improve healthcare significantly. We take a look at current annual reports and value chains.
Read